It has been well-known that miRNAs are involved in tumorigenesis or anti-tumorigenesis, functioning as oncogenic miRNAs or anti-tumor miRNAs. This mechanistically refers to the oncogenic miRNA-mediated repression of TET or other tumor suppressors. Recently, it was demonstrated that lnc-RNAs and circular RNAs (circRNAs) were also involved in tumorigenesis and progression via silencing of TET1 expression.

TET1 has been implicated for interplay with some anti-tumor miRNAs. For example, TET1 silencing led to significant down-regulation of miR-7 and miR-15/16 targeting to proto-oncogenes CdkK6, Mcf2L, and Edn1 and Wnt4 as well as Fzd4 components in the Wnt signaling pathway in papillary thyroid carcinoma (PTC). Consequently, the expression of these proto-oncogenes and the Wnt pathway was dramatically upregulated [96], and accordingly the cell proliferation and invasion were significantly enhanced. This suggests TET1 as a tumor suppressor for PTC and as a potential target for therapy of PTC patients [96].

TET1 has been characterized to interplay with anti-tumor lnc-RNA as well. As an example, the downregulation of lnc-01089, a lnc-RNA in GC tissues and cell lines caused an upregulation of miR-27a-3p and the subsequent repression of TET1. These molecular events led to the enhanced proliferation, migration, and invasion of GC cells. Associated phenotypes include larger tumor size, higher T-stage, and lymphatic metastasis in GC patients. Consistently, the lnc-01089 overexpression reversed all the phenotypes conferred by the downregulation of this lnc-RNA. Thus, the lnc-01089-miR-27a-3p-TET1 could potentially become therapeutic targets for GC [97].

TET1 functions as an indirect tumor suppressor and promoter in different cancers via interplay with some miRNAs that bear dual functions on promotion or repression of some cancers. For example, miR-34a could function as tumor suppression for lung tumorigenesis but as tumor promotion for breast cancer. It has been shown that 3,6-Dihydroxyflavone (DHF) activates miR-34a expression via elevation of TET1, which directly binds to its own promoter region [56] to regulate 5-hmC landscape. While DHF does not alter the binding of TET1 to its own promoter region, it could inhibit DNMT1 activity and hypermethylation, leading to enhanced demethylation of the TET1 promoter and activation of TET1 expression. Consequently, the elevated expression of TET1 enhances demethylation of the miR-34a promoter, leading to its activation and subsequent breast carcinogenesis [98]. However, miR-34a is crucially involved in repressing tumor progression through regulating epithelial-mesenchymal transition (EMT) via EMT-transcription factors, p53, and other essential signaling pathways [99].

TET1 is also involved in the circRNA-mediated epigenetic regulation of human retinoblastoma (HRB). The dynamic alteration of circRNAs was detected in HRB in in ways that circRNAs with increased expression, decreased expression, and unchanged expression relative to these in the adjacent tissue. Of the down-regulated circRNAs, some of their host genes were involved in chromatin modifications, such as TET1-has_circ_0093996 that takes TET1 as its host gene in HRB. The downregulation of the TET1-has_circ_0093996 was associated with the decrease of programmed cell death 4 (PDCD4) in the primary and recurrent HRB samples. Further bioinformatic study has established the complete regulatory axis TET1-has_circ_0093996-miR-183-PDCD4, suggesting the circRNA-based regulation on RB pathogenesis.

In addition to interaction with anti-tumor miRNAs, TET1 can also interplay with some miRNAs that could enhance tumorigenesis. For example, upregulation of miR-29a-5p accompanied by activation of the IL6-STAT3 pathway downregulated the expression of TET1 and TET3 consistently with lower levels of 5-hmC in colitis-associated colorectal cancer (CAC). In vitro knockdown of miR-29a-5p in cell lines could reverse the molecular events in TET and the IL6-STAT3 pathway. Thus, it could be inferred that the miR-29a-5p/STAT3/TET signaling axis may contribute to initiation of CAC and potentially serve as targets for therapy or prevention of CAC [100].

TET1 upregulation leads to hypomethylation of the BRCA1 promoter and upregulation of the DNMT3 confers hypermethylation of Synuclein Gamma gene (SNCG). Enhanced expression of TET1 is associated with down-regulation of miR-29b, suggesting Tet1 as a target of miR-29b. Therefore, the potential of the drug that bears the dual function on the regulation of promoter methylation/demethylation, may potentially become a promising therapeutic option for some cancers [101]. Similarly, overexpression of miR-29b associated with the downregulation of TET expression promotes cell proliferation, colony formation, migration, and EMT, suggesting miR-29b as a BC/GC promoter [102, 103]. Likewise, miR-21-5p and miR-4284 target and silence Tet1 expression in colorectal cancer (CRC) and GC SGC-7901 cells, respectively. Thus, both miR-21-5p and miR-4284 may serve as oncogenic biomarkers for diagnostics and prognostics in CRC and GC [104, 105].

Chronic inflammation leads to epigenetic alteration, in particular the methylation/demethylation mediated by DNMTs and TETs. Human gingival fibroblast exposure to IL-1$\beta$ led to DNMT1 upregulation and downregulation DNMT3a and TET1, while PGE2 downregulated all the three enzymes, altering the DNA modification patterns. The chronic inflammation-conferred alterations of DNMTS and TETs, as well as the downstream epigenome modification patterns, may contribute to the increased risk of tumorigenesis [106].

The $\beta$-catenin/Wnt signal pathway is involved in TET1 silencing. For example, TET1 expression was downregulated in both colon cancer tissues and cell lines. In vitroTet1 KD facilitated colon cancer cell proliferation and viability, associated with upregulation of $\beta$-catenin (CTNNB1) and the Wnt pathway. Consistently, CTNNB1 overexpression could recapitulate the similar phenotype caused by Tet1 downregulation. Knockdown of Tet1 could enhance expression of axis inhibition protein1 (AXIN1) and cell proliferation. However, double knockdown of both Tet1 and AXIN1 attenuated the cell proliferation and viability of the colon cancer, suggesting that TET1 functions as a colon cancer suppressor via the inhibition of the $\beta$-catenin pathway in AXIN1 dependent manner [107].

Another example is the silencing of TET1 expression mediated by the Wnt/$\beta$-catenin signaling pathway in tested epithelial ovarian cancer (EOC). Consistently, the ectopic expression of TET1 in SKOV3 and OVCAR3 cells led to the shrinking of colony formation and repression of cell migration/invasion. The related mechanism is the TET1 mediated demethylation and the consequent activation of SFRP2 and DKK1, the two key proteins in the Wnt/$\beta$-catenin signaling pathway [108]. In a separate report, significant downregulation of Tet1 expression failing to demethylate the promoter of the Ras association domain family member 5 (RASSF5) led to the silencing of RASSF5 in ovarian cancer, initiating tumorigenesis and promoting progression [109].

The epithelial-mesenchymal transition (EMT)-related oncogene pathway is silenced by TET1. TET1 promotes stemness properties in cervical cancer and inhibits EMT through 5hmC-dependent and -independent mechanisms. TET1-dependent elevation of 5hmC levels in the promoter regions of the ZEB1 and VIM genes doesn’t activate the expression of both genes. Instead, both genes were silenced. The silencing of the Zeb1 and Vimgenes attributes to loss of histone H3K4 and gain of histone H3K27 via interaction of TET1 with LSD1 and EZH2, the two histone modifiers. LSD1 and EZH2 are recruited by TET1 to the Zeb1 promoter, subsequently silencing Zeb1, an ETM-related oncogene [110, 111].

TET1 is silenced by EZH2 and H3K27me3 in triple-negative breast cancer (TNBC) cells, which lack the expression of ER, PR and HER2. High levels of EZH2 and low levels of TET1 in TNBC patients are associated with low survival rate. EZH2 downregulates TET1 expression via epigenetic regulation of H3K27me3, thereby blocking the p53 signaling pathway and leading to tumor progression. Consistently, knockdown of EZH2 with specific inhibitors GSK343 or shRNA, could upregulate TET1 and subsequently activate p53 pathway. It could also stimulate cell cycle arrest and senescence in TNBC cells. Thus, the EZH2-H3K27me3-TET1 axis could become a potentially promising therapeutic target via modulation of the epigenetic landscape [112].

Epidermal growth factor receptor (EGFR)-mediated TET1 repression promotes growth of some cancer cells, such as lung adenocarcinomas and glioblastomas HCC827/Del and HCC827/Del-T790M cell line. This suggests that TET1 may serve as a therapeutic target for lung cancers and glioblastomas both induced by oncogenic EGFR [113]. However, in human non-small cell lung cancer (NSCLC) patient samples, there was no EGFR-mediated TET1 silencing. Instead, a significant elevation of the TET1 expression level was detected in the patient tumor tissues with EGFR mutations. Thus, further studies are indispensable to explain the discrepancy between cancer cell lines and human cancer tissues [114].

A recent study discovered that oxidative stress leads to TET1 suppression and tumorigenesis. Treatment of mouse liver cells with cadmium (Cd) stimulated cell invasion. Molecularly, Cd treatment-induced oxidative stress, associated with overproduction of oxidative stress-sensitive metallothionein 2A (MT2A), led to suppression of TET1 and ApoE, but no effects were seen on DNMTs. Additionally, Cd could downregulate the expression of tissue inhibitors of metalloproteinase 2 and 3 (TIMP2 and TIMP3). The expression of ApoE, TET1, TIMP2, and TIMP3 was further suppressed by hydroquinone, a ROS species. However, the suppression was reversed by N-acetyl-l-cysteine (NAC), a ROS scavenger. Excitingly, the cell invasion induced by Cd was abolished by NAC. Therefore, the suppressed expression of TET1, ApoE, TIMP2, and TIMP3 by Cd and the induced ROS was likely involved in the enhanced invasiveness in response to Cd exposure. Anti-ROS could reverse the toxicity in terms of the Cd-induced malignancy [115].

TET1 is also silenced by the deficiency of key genes involved in base excision repair (BER). 5-mC/5-hmC levels were investigated in the 3-methylcholanthrene (3-MCA) induced cell malignant model, rat chemical carcinogenesis model, and human lung cancer tissues, respectively. The expression of XRCC1, OGG1, and APEX1 genes were crucial for the BER pathway and was significantly downregulated in response to 3-MCA treatment. Meanwhile, the expression of TET1 itself was suppressed by DNA methylation. Restoration of TET1 expression reversed the proliferation, migration, and invasion in the 3-MCA-induced malignant cells. Thus, TET1 could serve as a potential biomarker and therapeutic target for lung cancer [116].

Several natural or synthetic small molecules, such as eicosapentanoic acid (EPA), ML309, vitamin C (VC), chrysin, luteolin, and resveratrol (Res), have been identified to upregulate the expression of TET1 in cancer cells. In hepatocarcinoma cells, one of the major polyunsaturated fatty acids, could enhance rapid demethylation via the formation of PPAR$\gamma$-RXR$\alpha$-TET1 to recruit TET1 to a hypermethylated CpG region of the p21 gene promoter. Thus, the upregulation of the p21${}^{/Waf1/Cip1}$ could confer the anti-cancer effect by suppressing cancer cell-cycle progression. Therefore, EPA functions as a bridge linking TET1 to the expression of the anticancer gene, suggesting EPA as a potential therapeutic agent for solid tumors such as liver cancer [93].

Downregulation of TET1 inhibits AJAP1 expression via the reduction of 5-hmC levels at the promoter of adherens junctions associated protein 1 (AJAP1), subsequently activating $\beta$-catenin signaling to promote the development of urinary bladder cancer (UBC). Vitamin C (VC), a direct regulator of TET1 activity, could inhibit growth and tumorigenicity of UBC cells most likely via restoration of TET1. Thus, TET1 was proposed to be a UBC suppressor, and AJAP1 could be a promising prognostic biomarker for UBC patients as well as therapeutic targets [117].

IDH1 gene mutation leads to the generation of 2-hydroxyglutarate (2-HG), an oncometabolite that inhibits the activity of $\alpha$-kG dependent activity of TET enzymes. ML309, an inhibitor of mutant IDH enzymes, could decrease the 2-HG levels, partially alleviating toxicity to TET activity and playing a similar role as VC, an inducer of TET activity. While single treatment of the IDH mutant colon cancers with either ML309 or VC only led to limited improvement on TET activity, combinatorial treatment with both in mutant cells significantly elevated the global DNA 5-hmC levels, and the subsequent upregulation of expression of the gene encoding tumor suppressors. Moreover, a high percentage of apoptosis occurred in the mutated colon cancer cells treated with non-cytotoxic levels of the combined ML309 and VC, suggesting the combinatorial therapy could be promising for IDH1/2 mutated cancers [118].

Treatment of GC with chrysin, a natural compound frequently present in honey, could significantly upregulate the expression of TET1 and the subsequent elevation of 5-hmC in GC MKN45 cells, thereby inducing cell apoptosis and blocking cell migration/invasion. Thus, the anti-tumor effects of chrysin was mediated through upregulation of TET1 expression in GC, suggesting TET1 as a potentially novel target for GC therapy [119].

Luteolin, a dietary flavone, modulates numerous signaling pathways involved in carcinogenesis such as colon cancer via the downregulation of DNMTs, upregulating TET1 expression and enhancing recruitment of TET1 to the Nrf2 promoter region for hydroxymethylation to promote Nrf2 expression. In addition, the interaction of TP53 and Nrf2 enhances apoptosis. Therefore, this discovery not only partially elucidates the anticancer mechanism of luteolin but also suggests Nrf2 and Tet1 as the potential therapeutic targets for colon cancer and possibly other cancers [120].

Gastric adenocarcinoma (GA) with enteroblastic differentiation (GAED), a rare variant of aggressive adenocarcinoma, is frequently associated with mutation-caused TP53 inactivation. Of the characterized GAED cases, nearly 60% performed TET downregulation accompanied with the declination of 5-hmC levels, which is inversely associated with advanced stage, tumor size, and lymph metastasis. Approximately 70% of the cases with hypermethylation of the TP53 promoter is associated with the downregulation of TET1 and the reduced 5-hmC levels. Thus, it suggests that the promoter hypermethylation of TP53 caused by decreased levels of TET1 and 5-hmC partially contributes to loss of TP53 expression, further suggesting TET1 and TP53 as tumor suppressors and potential therapeutic targets for GA [121].

Resveratrol (Res), a natural compound, has been detected to suppress the migration and invasion of prostate cancer cells (PCCs) via the upregulation of TET1 expression. This enhanced the hydroxymethylation and expression of TIMP2 and TIMP3 but suppressed the expression of MMP2 and MMP9. Thus, the Res-mediated inhibition effect on the migration and invasion of PCCs was thought to be via the TET1/TIMP2/TIMP3 pathway, suggesting that this pathway may potentially be employed as a target for therapy [122].

Tet1 has been acknowledged as a tumor suppressor or oncogene depending on the cancer types. Osteosarcoma cells (U2OS) treated with hydroxyurea, an anti-cancer agent, led to TET1 upregulation associated with elevated levels of 5-hmC, enhanced apoptosis, inhibition of cell proliferation, and alteration of cell cycle, suggesting that TET1 could function as suppressor for osteosarcoma [123].

To identify new potential prognostic markers for head and neck squamous cell carcinoma (HNSCC), the promoter methylation status of five neuropeptide receptor genes was examined, including NTSR1, NTSR2, GHSR, MLNR, and NMUR1. Of the detected methylation status in the promoters of five genes, methylation status of GHSR and NMUR1 promoters could be utilized to predict recurrence in HNSCC independently. Combined data analysis of the methylation status of TET family genes indicated a trend toward greater methylation indices as the number of TET methylation events increased [124].

Chemoresistance is defined as the resistance of cancer stem cells (CSCs) or tumor initiating cells to a specific therapeutic agent. It refers to the resistance of a particular tumor to chemotherapy caused by DNA repairability, slower cell cycles, and multidrug resistance genes (MDR) such as P-glycoprotein (P-gp). The chemoresistance contributes to the setup of obstacles against chemotherapy. Of the resistance mechanisms characterized so far, TET-mediated epigenetic regulation plays a crucial role in the development of cancer progenitor cells invulnerable in exposure to conventional cancer therapies.

TET1 deficiency significantly contributes to gemcitabine resistance in cholangiocarcinoma (CCA) cell lines. Relative to normal CCA cells, TET1 is almost silenced, while expression of the P-gp encoded by one of the MDR genes is significantly upregulated. Consistently, TET1 overexpression significantly enhances the sensitivity of CCA cells to gemcitabine, in contrast to the dramatic downregulation of the P-gp expression in gemcitabine-resistant CCA cells. Altogether, it suggests TET1 as a potentially promising target to overcome the chemoresistance in CCA [125].

Unlike in CCA cell lines, TET1 enhances the progestin-based chemoresistance via the upregulation of expression of the glyoxalase I gene (GLOI) mediated by its promoter hydroxymethylation in type I endometrial cancer. The TET1-mediated progestin resistance was reversed by metformin treatment through the downregulation of the GLOI expression, further suggesting the contribution of the TET1-5hmC-GLOI signaling pathway to progestin resistance in endometrial cancer [126].

Several factors contribute to functional TET2 as a direct or indirect repressor, such as hydroxymethylation-independent tumor suppression, inflammatory stress, the interplay between TET2 and some miRNAs, the interplay between TET2 and DNMTs, etc. Downregulation of TET2 expression was detected in nasopharyngeal carcinoma (NPC) cells, while TET2 overexpression suppressed proliferation and invasion of the NPC cells. Interestingly, the effect of TET2 on the NPC phenotype was independent of TET2’s catalytic activity, suggesting the non-catalytic domain function of TET2 in tumor suppression. Molecularly, TET2 repressed proliferation and invasion via the suppression of glycolysis in NPC cells through the interaction of the TET2 N-terminal domain with PKM in the cytoplasm as well as the subsequential prevention of PKM dimers from translocating into the nucleus. Furthermore, TET2 KO performed opposite to TET2 overexpression in terms of NPC progression and survival rate in the xenograft tumor model. Therefore, both TET2 and PKM could potentially serve as targets for NPC therapy [133].

Inflammatory stress significantly contributed to the promotion of the initiation of pre-leukemic conditions and the aberrant expansion of myeloid cells associated with Tet2 deficiency. Importantly, antibiotic treatment could reverse the expansion of Tet2-deficient myeloid and lymphoid tumor cells in vivo promoted by inflammatory stress. Significant alteration in the expression of genes involved in the TNF-$\alpha$ signaling and other immunomodulatory pathways was detected in antibiotic-treated tumor cells. Furthermore, pharmacological inhibition of TNF-$\alpha$ signaling partially suppressed the proliferation of Tet2-deficient tumor cells in vivo, suggesting that pro-inflammatory pathways could serve as a promising target for therapy of TET2 deficiency-induced hematological malignancies [134].

Analogous to TET1, TET2 functions as a tumor suppressor via the interplay with some miRNAs. Overexpression of miR-210 in the lung cancer (LC)-derived exosomes was believed to enhance the angiogenesis levels in cancer-associated fibroblasts (CAFs), thereby initiating the CAF proangiogenic switch. MiR-210 contains numerous targets including Tet2 and some repressor genes for the JAK2/STAT3 signaling pathway. Therefore, its overexpression could downregulate TET2 expression and activate the JAK2/STAT3 signaling pathway, thereby facilitating the expression of some proangiogenic factors such as MMP9, FGF2, and VEGF. Consequently, it led to the proangiogenic switch of CAFs [135].

The miR-660-5p was reported to contribute to the pathogenesis of breast cancer (BC), lymph node metastasis, advanced TNM stage, and vascular invasion via the targeted downregulation of TET2 expression. The significant upregulation of miR-660-5p in BC was associated with the downregulation of TET2 and activation of the PI3K/AKT/mTOR signaling pathway, promoting BC cell proliferation and metastasis. In contrast, silencing of miR-660-5p reversed the promotion of BC. Therefore, miR-660-5p mediated promotion of BC progression, partially attributing to modulation of TET2 and PI3K/AKT/mTOR signaling, indicating miR-660-5p/TET2 as a promising therapeutic target for BC [136].

Some environmental pollutants may enhance the interplay of TET2 and DNMTs, resulting the downregulation of TET2 expression. Bisphenol A (BPA) and its homolog BSP, the environmental contaminants targeting disruption of estrogen receptors (ERs), have been implicated in the promotion of breast cancer via the ER$\alpha$ – DNMTs-TET2-DNA hydroxymethylation signaling pathway. The pathway initiates with the binding of BPA/BSP to ER$\alpha$, inducing activation of ER$\alpha$ via its homodimerization and phosphorylation. Once activated, the ER$\alpha$ binds to the promoter region of Dnmt1 and Dnmt3B to enhance their transcription, which is followed by binding of DNMT1 and DNMT3B to Tet2 promoter CpG islands and elevating the methylation level, leading to repression of Tet2 expression. The repressed expression of TET2 reduces 5hmC levels, contributing to the pathogenesis of enhancing the proliferation of breast cancer cells [137].

5-Aza, a DNA methyltransferase inhibitor (DNMTI), has been employed for clinical therapy for the higher-risk myelodysplastic syndromes (MDS). TET2 loss-of-function mutations lead to hypermethylation and impairs the expression of a subset of genes involved in erythroid differentiation in erythroleukemia cells. As one of the mechanisms, 5-Aza could reverse the molecular events induced by the TET loss of function, potentially suggesting the increased efficacy of 5-Aza in MDS patients harboring TET2 loss-of-function mutations [138].

Physical interaction of TET2 with the hydroxymethylated promoters of the signal transducer and activator of transcription factors (STATs) family members renders TET2 as a tumor suppressor. In the IFN-$\gamma$/JAK2/STAT1 signaling pathway, IFN-$\gamma$ interacts with its receptors to activate IFNGR-associated JAK1/2, causing phosphorylation of Tyr701 in STAT1 and translocation of the phosphorylated STAT1 to the nucleus. TET2 is recruited by STAT1 to the promoters of CXCL10 and PD-L1, leading to the dramatic increase of 5-hmC levels in these two promoter regions. Furthermore, this leads to the activation of both genes and constant promotion of cancer immunity/immunotherapy efficacy [139].

Down-regulation of the ZEB1-mediated TET2 expression could contribute to the pathogenesis of glioma. The expression levels of ZEB1 were significantly increased in the 42 of primary glioma tissues relative to the normal adjacent tissue samples. ZEB1 bound to the Tet2 promoter region led to repression of TET2 expression. Although the detailed mechanisms of how ZEB1 bound to the Tet2 promoter in glioma remains to be elusive, the current study suggests the downregulation of TET2 expression mediated by ZEB1 could contribute to the pathogenesis of glioma. This could shed a light on translation to clinical therapeutic strategies for glioma [140].

TET2 also functions as a suppressor for acute lymphoblastic leukemia (ALL) in children.

Low expression of TET2 in children with ALL is usually associated with poor prognosis. Thus, it was proposed that the TET2 expression levels could serve as a marker for risk assessment of 5-year overall survival (OS) and event-free survival (EFS) [141].

Natural small molecules functional as activators for TET2 activity could have anti-tumor functions, such as ascorbic acid (AA) otherwise known as VC. AA can restore TET activity via the facilitation of the Fe (III)/Fe (II) redox reaction. It has been implicated in the prevention and therapy of myeloid neoplasia (MN), caused by loss-of-function TET2 mutations (TET2MT). Mechanistically, the AA-based pharmacologic modulation of acetyltransferases and histone deacetylases could regulate the TET-dependent N- and C-terminal lysine acetylation albeit further investigations are required to clarify. Thus, this discovery could potentially suggest AA alone or the combination with class I/II HDAC inhibitor, sirtuin activators to act as therapeutic approaches for TET2M-based leukemia [142]. TET2 could be recruited and demethylate the promoter region of MMP9 to activate the expression of MMP9. Furthermore, the impact on the proliferation, migration, and invasion of HTR-8/SVneo cells in trophoblasts caused by downregulation of Tet2 could be rescued by AA, an activator of TET2 activity. Altogether, this suggests that MMP9 downregulation conferred by TET2 deficiency contributes to the pathogenesis of preeclampsia [143].

SLC2A3 is involved in the pathways such as the metabolism of water-soluble vitamins and cofactors as well as the HIF1 alpha pathway. Due to TET deficiency in particular TET2 in leukemogenesis, VC-based restoration of TET activity has been beneficial to AML therapy. However, SLC2A3 downregulation in AML severely blocked the absorption of VC, suggesting SLC2A3 as a potential biomarker for the VC-based therapy for AML [144].

Like TET1, TET2 deficiency could cause chemoresistance in head and neck cancer, GC, and BC cells. Failure to maintain the methylation/demethylation balance results in aberrant silencing or activation of the genes involved in tumorigenesis/suppression and contributes to pathogenesis, leading to chemotherapeutic resistance. TET2 is required to make some chemotherapeutic drugs (such as doxorubicin) functional for curing some cancers such as head and neck cancers via its demethylation activity to regulate gene expression and the resultant cell proliferation/migration. As an example, in response to doxorubicin, the physical interaction of TET2 with promyelocytic leukemia (PML) leads to the recruitment of TET2 to PML-positive nuclear bodies, thereby reactivating the silenced suppressor genes and subsequently impairing cell proliferation/migration. Thus, TET2 and PML could be the two promising therapeutic targets evidenced by the fact that PML KO abolished DNA modifications in response to doxorubicin. Indeed, the levels of PML and TET2 were positively correlated with overall survival in head and neck cancer patients [145].

TET2 is involved in the modulation of cisplatin resistance of GC cells as well in ways that significantly downregulated TET2 in cisplatin resistance SGC7901/DDP cells relative to the non-resistant cells. Accordingly, TET2 overexpression dramatically inhibited the cisplatin tolerance. As a mechanism, TET2 regulated the levels of interleukin-6, thereby modulating the cisplatin resistance via the regulation of histone acetylation. Thus, this study may uncover a novel mechanism of drug resistance in GC cells, potentially translating to the clinical approach for eradicating the drug resistance [146].

TET2 deficiency is also associated with chemoresistance in breast cancer cells. Clinically, chemoresistance to the poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) is common for treatment of breast and ovarian tumors caused by BRCA deficiency. In KB2P1.21 mouse mammary tumor cells, repressed TET2 expression led to the resistance to multiple PARPi, downregulating 5-hmC levels and protecting stalled replication forks (RFs) in the BRCA2-deficiency cells. TET2 expression-mediated 5-hmC abundance in the BRCA2-deficient mouse and human cancer cells induced the degradation of the stalled RFs via the recruitment of the base excision repair-associated apurinic/apyrimidinic endonuclease APE1, independent of BRCA2 status. Loss of 5-hmC and APE1 recruitment to stalled RFs due to TET2 deficiency promoted resistance to the chemotherapeutic cisplatin, suggesting a potential mechanism of the TET2-mediated epigenetic mark 5-hmC in resistance to PARPi and cisplatin by maintaining the integrity of stalled RFs [147].

TET2 was phosphorylated at tyrosines 1939 and 1964, which was activated by the cytokine-stimulated JAK2, leading to the enhanced interaction between TET2 and KLF1, an erythroid transcription factor. Thus, extracellular signals were linked to the epigenetic modifications mediated by TET2, leading to the upregulation of several oncogenes [148]. Sometimes, transcriptional activators that are unable to bind to DNA due to the lack of specific DNA binding domains can still recruit TET2 and activate specific target transcription factors via the ternary interaction among transcriptional coactivators. Via mammalian two-hybrid screening, multiple transcriptional regulators have been identified to interact with TET2. Of the identified TET2 interacting transcriptional activators, SNIP1, while possessing no specific DNA binding abilities, could recruit TET2 to several transcription factors, such as c-MYC. Thus, SNIP1 bridges TET2 to the promoters of c-MYC target genes via TET2-SNIP1-c-MYC ternary interactions to regulate target genes of these transcription factors [149].

Previous studies have indicated that TET2 functions as a tumor promoter via the aberrant AID pathway. In diffuse large B-cell lymphoma (DLBCL) patients who carry abnormal activation-induced cytidine deaminase (AID) expression, the enhanced demethylation mediated by TET2 on some proto-oncogene promoters could initiate or enhance oncogenesis. In this context, TET2 could function as an accomplice for DLBCL. Essentially, AID recruits TET2 to the promoter region of the dramatically expressed proto-oncogene Fanconi anemia complementation group A gene (FANCA), whereby the FANCA is activated via TET-catalyzed demethylation. Thus, AID, TET2, and FANCA work together to contribute to oncogenesis, suggesting that AID and TET2 could potentially become new therapeutic strategies for DLBCL [150].

Inactivating mutations of Tet2 are frequently found in human malignancies, suggesting the essential role of Tet2 in cellular transformation. Similar to AID in function of TET2, both MBD3 and MBD3L2 could specifically enhance the hydroxymethylation/demethylation activity of TET2 only, but not TET1 or TET3. Moreover, MBD3L2 could be functional more effectively than MBD3 via the enhancement of the binding affinity between the enzyme and the substrate of the methylated DNA. ChIP analysis identified the genomic binding sites co-occupied by MBD3L2 and TET2. The majority of the co-occupied regions belong to promoter elements for the genes involved in tumorigenesis such as XRCC6 and LDHB or the genes relating to metabolic regulation. Since TET2 does not contain the CXXC domain, it could be recruited by MBD3 and MBD3L2 or possibly by all the MBD family members to the appropriate genomic regions for the downstream events [151].

Significant attention has been paid to the functions of TET1 and TET2 in human cancers, particularly TET1and its role in oncogenesis or anti-tumor activity. Relative to TET1 and TET2, there remains limited information regarding the functions of TET3 in human cancers. However, based on the current studies, TET3 similarly functions as a tumor suppressor and promoter in a cancer-type-dependent manner.

TET3 has been proposed to be a candidate tumor suppressor for certain cancers such as GC, colorectal cancers (CRC), glioblastoma, and neck squamous cell carcinoma (HNSCC). Shift mutation of Tet3 gene harboring the mononucleotide repeats in the coding region leads to loss of TET3 expression in GC and CRC [152]. TET3 functioned as a tumor suppressor for glioblastoma tumorigenesis via the alteration of the 5-hmC landscape, evidenced by the fact that epigenetic downregulation of TET3 significantly declined the genome-wide 5hmC levels and promoted glioblastoma tumorigenesis, and vice versa. This suggests TET3 as a potential therapeutic target for glioblastoma [153].

To understand the functions of TET3 in tumorigenesis and the risk of disease recurrence in HNSCC, the methylation profiles of Tet1, Tet2, and Tet3 genes were generated in more than 200 tumor samples from HNSCC patients. It turned out that the simultaneous methylation of Tet genes was correlated with reduced disease-free survival and methylation levels of the tumor suppressor genes. In particular, the methylation events mediated by TET3 were independently and positively correlated with aggressive tumor performance and DNA methylation status globally in HNSCC, suggesting the predominant functions of TET3 over TET1 and TET2 in this regard [154].

Like TET2, TET3 serves as cancer promoter via the maintenance of cancer stem cells (CSCs) such as glioma stem cells (GSCs). Activation of the integrin $\alpha$6-FAK pathway through laminin-integrin $\alpha$6 in the extracellular matrix (ECM) could directly enhance STAT3 activity. This upregulates TET3, elevating 5-hmC levels of the promoter regions of the oncogenes, including c-Myc, critically involved in the maintenance of glioma stem cells (GSCs). Accordingly, silencing of TET3 in GSC-enriched tumors downregulated the expression of GSC critical genes, consequently inhibiting tumor growth. In this case, TET3 could function as a GSC promoter through the ECM- integrin $\alpha$6-STAT3-TET3 axis in a way that upregulates 5-hmC levels in the promoters of GSC critical genes, leading to the promotion of GSC tumorigenicity and therapy resistance [155].

TET3 also functions as a cancer promoter by maintaining the stemness of some cancer cells such as in esophageal squamous cell cancer (ESCC). Significant accumulation of lipopolysaccharide (LPS) was detected in ESCC, facilitating stemness of the ESCC cells via the sequential stimulation of the TET3/p38/ERK-MAPK pathway in ESCC and consequently leading to poor ESCC patient survival. Enhanced TET3 expression increased the expression of its target HOXB2 via the elevation of 5-hmC levels at the HOXB2 promoter. ChIP results demonstrated that HOXB2 bound to the genomic loci of Nanog and c-Myc initiated or facilitated the stemness of ESCC. Therefore, LPS served as an ESCC promotor via ESCC stemness through the activation of the LPS-TET3-HOXB2 signaling axis potentially serving as a novel therapeutic target for ESCC [156].

Some environmental toxicants, such as glyphosate, could render TET3 functions as tumor promoter as well. The known effect of glyphosate on estrogen-regulated signaling leads to its suspected pathogenesis to breast cancer. However, there is no evidence to show that the nonneoplastic MCF10A cells treated with the glyphosate alone could induce tumorigenesis. This suggests a synergistic effect of some environmental toxicants such as glyphosate with other endogenous factors triggering tumorigenesis. Unlike the UP peptide, a strong demethylating agent and a cancer promoter function via the DNMT1/PCNA/UHRF1 pathway. Glyphosate significantly elevated demethylation levels by enhancing TET3 activity. Synergistic exposure to glyphosate plus upregulation of miR182-5p significantly led to tumor development. Consistently, downregulation of miR182-5p or treatment with dimethyloxallyl glycine, an inhibitor of the TET pathway, could prevent oncogenesis. Thus, this discovery indicated that the low pressure from the TET pathway-mediated DNA hypomethylation could stimulate the cells for tumorigenic responses if in the presence of another potential risk factor [157].